RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biomarkers biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 PMA postmarketing protocol safety statistical analysis toxicology transparency vaccines venture capital webinarCategories
- Clinical Trials (55)
- Conferences and Meetings (35)
- eCTD (26)
- FDA (78)
- Guest Posts (5)
- Health Canada (6)
- Industry News (62)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (39)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: Cato BioVentures
2010 Mid-Atlantic Bio Conference
Image via Wikipedia The 2010 Mid-Atlantic Bio conference will be held in Bethesda, MD from Wednesday, 27 October to Friday, 29 October. Mid-Atlantic Bio is now in its sixth year and has become one of the country’s premier bioscience and … Continue reading
Posted in Conferences and Meetings, Venture Capital
Tagged BIO, bioscience, biotech, Cato BioVentures, Cato Research, FDA, venture capital
Comments Off
35th European Society for Medical Oncology Congress
Image via Wikipedia The annual European Society for Medical Oncology (ESMO) meeting brings together medical oncologists from both Europe and all parts of the world. As per ESMO’s 2010 meeting President, Dr. David Kerr, announcement: The ESMO Congress is a … Continue reading
Use A Detailed Development Plan to Secure Venture Capital
It’s a tough time to be asking for money. Whether you’re a high schooler who needs cash to gas up the ride or a fledgling biotechnology company with a hot technology, there’s not much extra to go around. In today’s … Continue reading
Posted in Venture Capital
Tagged biologics, business plan, Cato BioVentures, CDRH, development plan, drug development, FDA, venture capital
1 Comment
Approval of Therapeutic Cancer Vaccines
Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Provenge is the first cancer treatment that utilizes the strength of the … Continue reading
Posted in FDA, Industry News, Publications
Tagged biomedical, cancer, Cancer Advances, cancer vaccine, Cato BioVentures, clinical benefit, clinical development, Dendreon, drug development, gastric cancer, gastrointestinal cancers, immune system, immunomodulators, Journal for Clinical Studies, monoclonal antibody therapy, pancreatic cancer, Provenge, serum-derived polyclonal treatment, targeted therapeutics, tumors
1 Comment
Cato at BIO 2010
The BIO International Convention is the largest global event for the biotechnology industry. It attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. This year’s … Continue reading
Posted in Conferences and Meetings
Tagged BIO, BIO 2010, biotech, Cato BioVentures, Cato Research, Chicago, CROs, Quebec
Comments Off
